Background: Members of the glutathione S-transferase (GST) superfamily are important in cellular defense mechanisms. These enzymes attach reduced glutathione to electrophilic groups in a wide variety of toxic compounds, including chemotherapeutic agents. Certain polymorphisms in GSTs are associated with changes in enzyme activity, sensitivity to chemotherapy, and overall patient survival. In a retrospective study, we investigated associations between common polymorphisms in genes for several GST subclasses (GSTP1, 
In the post-genomic era, the possibility of individualizing cancer treatment is gaining wide acceptance. Resistance to chemotherapy and toxicity of specific agents are largely determined by multifaceted enzymatic systems that are cytotoxic targets or members of the metabolic pathway of the administered drug. Numerous genetic polymorphisms that may be involved in differential enzyme function or expression, cancer risk, and clinical response to chemotherapy have been identified (1) (2) (3) . One of the remaining challenges is to identify markers that dramatically influence clinical outcome to specific chemotherapeutic agents.
Glutathione S-transferases (GSTs), a superfamily of dimeric phase II metabolic enzymes, play an important role in the cellular defense system. GST enzymes catalyze the conjugation of toxic and carcinogenic electrophilic molecules with glutathione and thereby protect cellular macromolecules from damage (4) . Growing evidence indicates that GST enzymes determine cytotoxicity of a variety of chemotherapeutic drugs (5, 6) . Five subclasses of the GST superfamily exist (Alpha, Pi, Mu, Theta, Zeta) (7) . The subclass GSTP1 is widely expressed in normal human epithelial tissues and has been shown to be highly overexpressed in colon cancer (8) . Drug-resistant tumors were found to contain increased levels of GSTP1 (9) . GSTP1 directly participates in the detoxification of platinum compounds and is an important mediator of both intrinsic and acquired resistance to platinum (10, 11) . In addition to GSTP1, the activity of GSTM1 and GSTT1 may be implicated in the development of certain cancers and response to treatment (12) .
Three common polymorphisms in the GSTP1, GSTT1, and GSTM1 genes either decrease or abolish GST enzyme activity. A single nucleotide substitution (A→G) at position 313 of the GSTP1 gene, which results in replacing isoleucine with valine, substantially diminishes GSTP1 enzyme activity (13) . By contrast, inherited homozygous deletions of the GSTT1 or GSTM1 gene lead to an absence of enzymatic activity (14) .
Oxaliplatin is one of the most promising new drugs in the treatment of colorectal cancer, where its synergistic effects with 5-fluorouracil (5-FU) lead to response rates up to 25%, even in heavily pretreated patients with relapsing disease (15) . Given the biochemical evidence that GST mediates inactivation of platinum drugs, we analyzed the common polymorphisms in three genes (GSTP1, GSTT1, and GSTM1) in 107 previously treated patients with metastatic colorectal cancer to determine whether the presence of one or more of the polymorphisms is associated with clinical outcome to 5-FU/oxaliplatin chemotherapy.
SUBJECTS AND METHODS

Eligible Subjects
From 1998 through 2000, 183 patients with metastatic colorectal cancer were enrolled in the oxaliplatin protocol 3C-98-3 for pretreated colorectal cancer patients at the University of Southern California/Norris Comprehensive Cancer Center. One hundred seven of these 183 patients were eligible for the analysis. This study was conducted at the Norris Comprehensive Can-cer Center and approved by the Institutional Review Board of the University of Southern California for Medical Sciences. All patients signed an informed consent form before entering the study. Patients entered in the treatment protocol also signed an informed consent form for blood sample collection to establish the clinical significance of genetic polymorphisms in gastrointestinal cancer. All specimens (blood samples) were obtained at the time of treatment protocol entry. The age, race/ethnicity, and follow-up information for each subject were obtained from the clinical trials database at the Norris Comprehensive Cancer Center. The clinical data and specimens were evaluated retrospectively. Patients' performance status was classified according to Eastern Cooperative Oncology Group (ECOG) criteria (16) . Patients with an ECOG status greater than 2 were not eligible for this study.
All patients enrolled in the study had advanced colorectal tumors and had been previously treated with 5-FU. A secondline treatment with irinotecan (CPT-11) had failed in the majority of patients (84/107; 79%). For this study, all participants received the following combination therapy regimen: oxaliplatin (130 mg/m 2 ) as a 2-hour infusion every 3 weeks and 5-FU (200 mg/m 2 /day) weekly as a continuous infusion for 10 weeks followed by 2 weeks of rest.
All patients were required to have bi-dimensionally measurable disease at the time of protocol entry. To be evaluable for response to therapy, a patient was required to have completed two cycles of therapy or to have progressed before completing two cycles. Clinical response to therapy was defined as a decrease in tumor burden (the sum, over all measurable lesions, of the products of the largest diameter and its perpendicular diameter) of 50% or more for at least 6 weeks. Progressive disease was defined as an increase in tumor burden of 25% or more (compared with the smallest measurement) or the appearance of new lesions. Patients with stable disease were those who did not experience a response and did not progress within the first 12 weeks after starting 5-FU/oxaliplatin therapy.
Genotyping
GSTP1 polymorphism. Genomic DNA was extracted from 200 L of whole blood using the QiaAmp kit (Qiagen, Valencia, CA). The Ile
105
Val polymorphism was analyzed by the polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) technique as described by Harries et al. (17) . Briefly, 5 L of the cell lysate was used as a template together with 200 ng of each primer 105F (5Ј-ACCCCAGGGCTCTATG-GGAA-3Ј) and 105R (5Ј-TGAGGGCACAAGAAGCCCCT-3Ј), 2.0 mM MgCl 2 , and 1.5 U Taq DNA polymerase (Applied Biosystems, Branchburg, NJ) in a total volume of 40 L. The annealing temperature was 55°C, and 30 PCR cycles were carried out. The PCR product was digested with 5 U BsmAI, and the fragments were separated on a 3.0% Metaphor® agarose gel (FMC Bioproducts, Rockland, ME) and visualized after staining with ethidium bromide.
GSTM1 and GSTT1 polymorphisms. The presence or absence of the GSTT1 or GSTM1 genes was determined simultaneously using a multiplex PCR protocol (18) , with the following modifications. The primers for GSTM1, GSTT1, and albumin (18) were at the final concentration of 50 pmol per 30-L PCR. The polymerase used was rTaq (Pharmacia, Piscataway, NJ). The resulting PCR fragments were separated on a 2.0% Metaphor® agarose gel (FMC Bioproducts) and visualized after staining with ethidium bromide.
Statistical Analysis
GSTP1, GSTT1, and GSTM1 polymorphisms were analyzed separately. The purpose of each analysis was to evaluate the association between the polymorphisms and demographic data, pretreatment characteristics, or outcome, i.e., response to chemotherapy, toxicity, and survival.
Contingency tables and Fisher's exact test (19) were used to determine the relationship between each categorical variable with the GSTP1, GSTT1, and GSTM1 genotype. Patients' baseline and pretreatment characteristics as well as toxicity and response to chemotherapy were summarized by groups.
Survival was calculated as the time from the start of oxaliplatin treatment until death from any cause or until last contact if the patient was known to be alive. Differences in survival were tested using the log-rank test (20) . For the univariate analyses, the Pike estimate of relative risk (RR) based on the log-rank test (21) was used to provide a quantitative summary of the data with 95% confidence intervals (CIs) (22, 23) . Initially, univariate survival analyses were used to evaluate the association with all the prognostic factors. The univariate analysis demonstrated that tumor differentiation, patient's performance status, and site of tumor were statistically significantly related to survival at the alpha ‫ס‬ 0.05-level of significance on the basis of the log-rank test. When we examined these three variables together, tumor differentiation was no longer statistically significantly associated with survival. Therefore, performance status and tumor side were combined to create three strata for statistical adjustment purposes: ECOG 0-1 and left-sided tumor, ECOG 0-1 and rightsided tumor, and ECOG 2. The association between GSTP1 genotypes and survival was reevaluated using the log-rank test, stratified by this new performance status and site variable. The median survival, Kaplan-Meier plots (24), RRs and associated 95% CIs, the probabilities of survival at 18 months, and Greenwood's standard errors (25) were used to summarize the data overall, stratified and within subgroups. All statistical tests were two-sided. Analyses were performed using Statistical Analysis System (SAS), version 8.2 (SAS Institute, Cary, NC) and Epilog (Epicenter Software, Pasadena, CA).
RESULTS
Patients
Among the 183 patients enrolled in this study from 1998 through 2000, we obtained blood samples from 107 patients for the GST genotype analysis (Table 1 ). This group of 107 patients included 30 (28%) women and 77 (72%) men. The median age was 60 years (range 24-83 years). The ethnic backgrounds were as follows: 72% (77/107) Caucasian, 13% (14/107) Hispanic, 10% (11/107) Asian, and 5% (5/107) African-American. The median overall survival time was 9.6 months (95% CI ‫ס‬ 7.9 to 12.3 months) with a median follow-up period of 10.9 months (range 0.82 to 26.5 months). Fifty-four percent (58/107) of the study participants died from the disease during the follow-up period.
Of the 107 patients, 101 (94%) could be evaluated to deter-mine a clinical response to treatment. Of these 101 patients, 9 (9%) responded to the treatment, 71 (70%) showed stable disease, and 21 (21%) showed progressive disease. Six patients withdrew from the study too early to evaluate their response. Of these patients, three refused further therapy after the first course, one was removed from the study on the basis of the physician's decision, one died, and one was removed from the study because of grade 3 toxicity. Forty-seven percent (50/107) of patients experienced grade 3 or 4 treatment-related toxicity. The most common side effects of the treatment were gastrointestinal toxicity, which occurred in 66% (33/50) of patients, and neurological toxicity, which occurred in 20% (10/50) of patients. All other patients showed toxicities of grade 2 or lower.
Survival Analysis (Demographic, Clinical, and Pathologic Characteristics)
Age, ethnicity, and sex were not associated with patient survival. The estimated survival probability was 0.24 (95% CI ‫ס‬ 0.10 to 0.38) at 18 months for patients with well or moderately differentiated tumors, compared with 0.10 (95% CI ‫ס‬ 0.00 to 0.28) for patients with poorly differentiated tumors (P ‫ס‬ .02). At 18 months, patients with a right-sided tumor had an estimated survival probability of 0.06 (95% CI ‫ס‬ 0.00 to 0.18), compared with patients with a left-sided tumor who had an estimated survival probability of 0.33 (95% CI ‫ס‬ 0.15 to 0.51; P<.001). At 18 months, the estimated probability of surviving was 0.32 (95% CI ‫ס‬ 0.16 to 0.48) for patients with an ECOG performance status of 0-1, compared with 0.00 for patients with an ECOG performance status of 2 (P<.001, Table 1 ). The number of metastatic sites, the localization of the metastases (lung versus liver), and the pretreatment (CPT-11 versus no CPT-11) were not associated with survival (data not shown).
GSTP1 polymorphism. Val allele was 0.30 (65/214) and was similar to previous reports that frequency in healthy Caucasians and AfricanAmericans (13) and in colorectal cancer patients (26) .
No association was observed between the demographic characteristics of the study participants (age, sex, and ethnicity) and the GSTP1 genotypes. Clinical (toxicity and response) and pathologic (histology, number of metastases, site of metastasis [liver versus lung]) characteristics were not statistically associated with GSTP1 genotypes ( (Fig. 1, Table 3 ).
The number of GSTP1 *If the relative risk is greater than 1, the relative risk can be thought of as the average increased risk of dying at any point in time compared with the reference group. The group with the ratio equal to 1.00 is the reference group.
†P value based on log-rank test (20). ‡Performance status was defined according to the Eastern Cooperative Oncology Group (ECOG) Criteria for Toxicity and Response (15).
Analysis of the association between the GSTP1 genotype and survival, stratifying by tumor location (tumors on the left versus the right side) and by performance status (ECOG 0-1 versus ECOG 2), demonstrated a consistent reduction of RR with an increase in the number of 105 Val alleles. After stratification by performance status and tumor side, the RR of dying for patients homozygous for the 105 Val allele was 0.28 (95% CI ‫ס‬ 0.07 to 1.10) (Table 4) . GSTT1 and GSTM1 polymorphisms. GSTT1 and GSTM1 genotypes were assessed for 99 (93%) of 107 patients. The frequencies (number of alleles/number of chromosomes) of the GSTT1 and GSTM1 gene deletions were 0.45 (i.e., 45 of 99 patients had deletions) and 0.27, respectively. Eleven patients (11%) showed a deletion of both genes.
GSTT1 and GSTM1 genotypes were not associated with demographic, pathologic, or clinical characteristics. For patients in the study, survival or risk of dying was not associated with GSTT1 or GSTM1 genotypes in single or combined analysis (Table 3) .
DISCUSSION
Our analysis of the common polymorphisms for three genes of the GST family in patients with advanced colorectal cancer demonstrates that relevant alteration of a protein's function can result in differences of defined clinical endpoints.
GSTs catalyze the first step in the formation of mercapturic acids, initiating a pathway that results mostly in the elimination of toxic compounds (27) . Previous studies (13, 28) revealed that substitution of isoleucine with valine at codon 105 alters the function of the GSTP1 protein. Watson et al. (13) demonstrated that individuals with two GSTP1 valine alleles had a lower catalytic activity compared with individuals with two GSTP1 isoleucine alleles. An intermediate activity was reported for heterozygotes (13, 28) .
In this study, we demonstrated that among colorectal cancer patients who received 5-FU/oxaliplatin chemotherapy, those possessing the GSTP1 105 Val variant allele showed a statistically significant reduction in the risk of dying. The reduction increased with the number of GSTP1 105 Val alleles. This allelecopy-dependent reduction in risk was independent of other welldefined clinical and pathologic prognostic markers such as tumor differentiation, performance status, and side of tumor location. The survival benefit for patients with left-sided cancers in our study is in agreement with a recent study of 656 patients with Dukes' C colorectal cancer by Elsaleh et al. (29) , which showed worse overall survival for patients with right-sided tumors. Although Gryfe et al. (30) did not find an association between tumor site and survival, this may be attributed to the fact that stages of the disease were mixed in that study. Our results suggest that GSTP1 may be an important player in the metabolism of platinum drugs. The results support the hypothesis that the effects of chemotherapeutic drugs might be altered when enzymes that could enhance the elimination of these drugs show a reduced activity.
This hypothesis is further supported by biochemical studies (10, 11) and clinical reports (31, 32) that provide strong evidence for a direct involvement of GSTP1 in resistance to platinum compounds. Recently, Goto et al. (10) showed that GSTP1 is directly involved in the detoxification of cisplatin by the formation of cisplatin-glutathione adducts, suggesting that GSTP1 plays a role in the acquisition of resistance to this platinum compound. Transfection analysis with GSTP1 antisense complementary DNA in colon cancer cell lines revealed that GSTP1 was responsible for both intrinsic and acquired resistance to several drugs, including platinum (11) . Clinical reports by Nishimura et al. (31) and Shiga et al. (32) on head and neck cancers also reflect the important role of GST enzymes in the metabolism of platinum drugs. The majority of patients who showed a low GST protein expression level responded to a platinum-based treatment and had better survival when compared with patients with a high tumor GST expression profile.
Recent clinical reports provide evidence for an association between GSTP1 genotype and cytotoxicity of chemotherapeutic agents (33, 34) . A retrospective analysis among 240 women with breast cancer revealed a trend toward superior overall survival of patients who carry the GSTP1 105 Val allele, suggesting a determining role of the GSTP1 genotype in cytotoxicity of chemotherapy (33) . The influence of the GSTP1 genotype was not restricted in response to a single chemotherapeutic agent, because a wide variety of different treatments were used. The beneficial effect of the 105 Val allele could not be attributed to a specific drug or drug combination.
Furthermore, the influence of the GSTP1 genotype was not restricted to solid cancers. The influence of the GSTP1 105 Val allele on enzyme activity is supported by a recent study that evaluated the association between the GSTP1 polymorphism Val allele were more likely to develop a therapy-related acute myeloid leukemia (34) .
All patients in our study had metastatic colorectal cancers and received 5-FU/oxaliplatin combination chemotherapy. In vitro studies have shown that GSTP1 is involved in the detoxification of platinum compounds, especially cisplatin (10, 11, 27) . No information is available on the possible impact of GSTP1 on the oxaliplatin pathway. The impact of GSTP1 on 5-FU metabolism is currently controversial. Although Zhan and Liu (35) showed a decrease of GSTP1 levels after 5-FU treatment, Nishiyama et al. (36) showed an increase in GSTP1 expression. Currently, it is unknown if GSTP1 participates in the detoxification of 5-FU.
Clinical studies have implicated GSTP1 as a predictive marker for clinical outcome in cancer patients treated with platinum-based chemotherapy (31, 32) . Results from our current study support the predictive value of GSTP1 in platinum-based chemotherapy, but biochemical studies are needed to definitively demonstrate that GSTP1 is directly involved in the detoxification of oxaliplatin. Moreover, patients in our study received combination chemotherapy of 5-FU and oxaliplatin. Although strong biochemical evidence is lacking for a detoxification of 5-FU by GSTP1, from our current study we cannot attribute the beneficial effect of reduced GSTP1 function to an alteration of the activity of the platinum compound alone.
Deletion polymorphisms in the GSTT1 or GSTM1 genes
were not associated with survival in this study. Studies by Ambrosone et al. (37) and Davies et al. (38) demonstrated an association between polymorphisms of GSTT1 and GSTM1 and clinical outcome in patients with breast cancer or childhood leukemia. To our knowledge, there are no reports linking these polymorphisms to clinical responses or survival of patients with colorectal cancer treated with chemotherapy. GSTT1 and GSTM1 are expressed at low levels in colorectal tumor tissue. By contrast, GSTP1 has been shown to be highly expressed in colon cancer (8) . The reduced GSTM1 and GSTT1 expression in colorectal tissue may explain the lack of impact these genes have on survival and chemotherapy responses in patients with colorectal cancer.
In recent years, a growing number of novel anticancer agents for the treatment of colorectal cancer have been developed. Oxaliplatin is one example. Coupled with the variety of options, the ability to identify patients who will be more sensitive or resistant to a specific chemotherapeutic agent carries important clinical implications. Genetic profiles of individual cancer patients have the potential to aid in making treatment decisions. A recent report also points to the importance of GSTP1 in the metabolism of TLK286, a promising new anticancer agent (39) . Our study suggests that GSTP1 genotyping of individual colorectal cancer patients might contribute to improved therapy planning. However, we evaluated only a relatively small number of patients (107), who all received an identical platinum-based chemo- therapy. Furthermore, an association between the GSTP1 genotype and the response to chemotherapy could not be determined. Therefore, our data should be considered as preliminary results, and randomized clinical trials with different treatment arms are needed to confirm a survival benefit for patients who possess the 105 Val/ 105 Val GSTP1 genotype and who are being treated with platinum drugs. †If the relative risk is less than 1, the relative risk can be thought of as the average decreased risk of dying at any point in time compared with the reference group. If the relative risk is greater than 1, the relative risk can be thought of as the average increased risk of dying at any point in time compared with the reference group.
[The group with the ratio equal to 1.00 is the reference group.]
‡P value based on log-rank test (20) . §Median follow-up is 10.9 (range ‫ס‬ 0.82 to 26.5) months.
A genotype was defined as positive if at least one copy of the gene was present. 
